CJC-1295 + Ipamorelin
Research Use Only · Not for Human Consumption
A research blend of CJC-1295 and Ipamorelin, two synthetic growth-hormone-releasing peptides, supplied in lyophilized form.
A research blend of CJC-1295 and Ipamorelin, two synthetic growth-hormone-releasing peptides
Blend Components
| Component | CAS# | Formula | Molar Mass |
|---|---|---|---|
| CAS Number: CJC-1295 | Molecular Formula: 863288-34-0 | Molar Mass: C165H271N47O46 | 3647.28 g/mol |
| Ipamorelin | 170851-70-4 | C38H49N9O5 | 711.85 g/mol |
What is CJC-1295 + Ipamorelin?
A two-peptide research blend combining CJC-1295, a synthetic GHRH analog, and Ipamorelin, a synthetic pentapeptide ghrelin-receptor (GHS-R1a) agonist. Each component has been examined in preclinical publications for interactions with distinct receptors involved in growth-hormone secretion signaling.
This blend brings together two peptides with different origin stories. CJC-1295 was developed by ConjuChem Biotechnologies, a Canadian biotech company, in the early 2000s as a long-acting synthetic analog of growth-hormone-releasing hormone (GHRH) for use in preclinical research.
Ipamorelin was characterized in the late 1990s by researchers at Novo Nordisk in Denmark as part of a program investigating selective growth-hormone secretagogues. Published research described it as a pentapeptide agonist at the GHS-R1a (ghrelin) receptor, noted in the literature for its selectivity relative to earlier GH-secretagogue compounds.
Subsequent preclinical publications have examined CJC-1295 for its effects on GH pulse amplitude via GHRH-receptor signaling, and Ipamorelin for its effects on pulse frequency via GHS-R1a signaling. Combination research has examined these dual-mechanism interactions at the level of the GH/IGF-1 axis in laboratory settings.
CJC-1295 and Ipamorelin continue to appear in peer-reviewed preclinical publications investigating growth-hormone-secretagogue pharmacology. This product is intended for research use only.
How should CJC-1295 + Ipamorelin be stored?
Peptide Foundry research peptides are supplied lyophilized (freeze-dried). Keep sealed vials cool, dry, and protected from light until reconstitution.
After reconstitution, refrigerate prepared solutions and use sterile technique. For general laboratory diluent and handling notes, see lyophilized peptide reconstitution.
Certificate of Analysis
Every batch of CJC-1295 + Ipamorelin is tested by Freedom Diagnostics for purity, identity, heavy metals, sterility, and endotoxin. The full certificate is below.
CJC-1295 / Ipamorelin · 5mg/5mg
Peptide Purity · HPLC @ 214 nm
99.97% — exceptional research-grade purity
Area-normalized against all peptide-related peaks. Identity confirmed by chromatographic retention-time match to a reference standard.
Every test on this certificate
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Related Research Compounds
Frequently purchased with CJC-1295 + Ipamorelin
Add all 3 items to your cart
$345
Further reading
References
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PubMed: 17018654
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed: 16352683
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed: 9849822
- Gobburu JV, Agersu00f8 H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PubMed: 10496658
